5-Acetyl-2-arylbenzimidazoles as antiviral agents. Part 4
摘要:
Within a project aimed at discovering new Flaviviridae inhibitors, new variously substituted 2-phenylbenzimidazoles were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representatives of the three genera of the Flaviviridae family, i.e.: Pestivirus (BVDV), Flavivirus (YFV) and Hepacivirus (HCV). Title compounds were also tested against RNA viruses representative of other single-stranded, positive-sense (ssRNA(+)) negative-sense (RNA(-)), or double-stranded (dsRNA) genomes, as well as against representatives of two DNA virus families.Nine compounds showed activity against BVDV (EC50 = 0.8-8.0 mu M), compound 31 being the most potent (EC50 = 0.80 mu M) and selective (SI = CC50/EC50 = >100). When tested in an HCV replicon assay, compound 31 resulted again the most potent, displaying an EC50 value of 1.11 mu M and an SI of 100. Besides inhibiting BVDV, two compounds (35 and 38) showed a moderate activity also against YFV (EC50 = 13 mu M). Interestingly, 35 was moderately active also against RSV (EC50 = 25 mu M). (C) 2012 Elsevier Masson SAS. All rights reserved.
Seventy-six 2-phenylbenzimidazolederivatives were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. The most commonly affected viruses were, in decreasing order, CVB-2, BVDV, Sb-1, HSV-1, and YFV, while HIV-1 and VSV were not affected, and RSV, VV and Reo-1 were only susceptible to a few compounds. Thirty-nine compounds
4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
申请人:Actelion Pharmaceuticals Ltd.
公开号:US20140371204A1
公开(公告)日:2014-12-18
The invention relates to compounds of Formula (I) wherein ring A, X, (R
1
)
n
, R
2
, R
3
, R
4
, R
4′
, R
5
, n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.
A short route to a series of 2′-deoxy-C-nucleosides featuring substituted nucleobases has been developed. The key step is the formation of the cyclized products following Mukaiyama's type amide coupling and a simple dehydration, starting from readily accessible synthons. The epimerization of the C1′-stereogenic center was avoided under mild and controlled conditions.
[EN] AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS<br/>[FR] AMINO-BENZAZOLES UTILISES COMME INHIBITEURS DU RECEPTEUR P2Y1
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2005070920A1
公开(公告)日:2005-08-04
The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
<i>meta</i> C–H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity
作者:Luo-Yan Liu、Jennifer X. Qiao、Kap-Sun Yeung、William R. Ewing、Jin-Quan Yu
DOI:10.1021/jacs.9b07887
日期:2019.9.18
report the first catalytic system that effectively performs meta C-Harylation of a variety of alkoxy aromatics including 2,3-dihydrobenzofuran and chromane with exclusive meta site-selectivity, thus reversing the conventional site selectivity governed by native electroniceffects. The identification of an effective ligand and modified norbornene (NBE-CO2Me), as well as taking advantage of the statistics